Recent ECDC data show that despite progress in prevention and control efforts, the hepatitis B and hepatitis C viruses (HBV and HCV) continue to pose significant public health challenges in the European Union and European Economic Area (EU/EEA).
Since April 2023, over 300 shigellosis cases, many with multidrug-resistant Shigella sonnei -infections, have been reported to the European Centre for Disease Prevention and Control (ECDC).
Increased numbers of shigellosis cases, mainly caused by Shigella sonnei, among travellers returning from Cabo Verde, have been reported in the EU/EEA, the United Kingdom (UK) and the United States (US) since September 2022.
A number of European countries (including Ireland, France, the Netherlands, Sweden and the United Kingdom) indicate an increase seen during 2022, particularly since September 2022, in the number of cases of invasive Group A Streptococcus (iGAS) disease among children less than ten years of age.
ECDC provides support to EU/EEA countries in monitoring their progress towards the hepatitis elimination targets and has just published a report based on the second data collection.
ECDC coordinates the enhanced surveillance for hepatitis A, B and C to help countries define epidemiological trends or transmission patterns among newly diagnosed cases.
World Hepatitis Day on 28 July provides an opportunity each year to increase the awareness and understanding of viral hepatitis.